Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd W Miller

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Endocrine resistance: what do we know?Todd W Miller
Expert Review of Endocrinology & Metabolism|February 14, 2019
Membrane-initiated estrogen signaling: oncogenic or impotent?Todd W Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Managing breast cancers with low estrogen receptor and HER2 by drugging bothTodd W Miller
Breast Cancer Research : BCR|February 10, 2012
Initiating breast cancer by PIK3CA mutationTodd W Miller
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Intrabody applications in neurological disorders: progress and future prospectsTodd W Miller, Anne Messer
The Oncologist|November 22, 2017
Trailblazing Precision Oncology for Rare Tumor SubtypesKevin Shee, Todd W Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2023
Alpelisib Efficacy without Cherry-PI3King MutationsSteven Tau, Todd W Miller
Cancer Metastasis Reviews|January 25, 2023
The role of cancer cell bioenergetics in dormancy and drug resistanceSteven Tau, Todd W Miller
Plos One|November 26, 2019
Statistical determination of synergy based on Bliss definition of drugs independenceEugene Demidenko, Todd W Miller
Pharmacogenomics and Personalized Medicine|September 11, 2014
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathwaysSarah R Hosford, Todd W Miller
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Endocrine resistance: what do we know?Todd W Miller
Expert Review of Endocrinology & Metabolism|February 14, 2019
Membrane-initiated estrogen signaling: oncogenic or impotent?Todd W Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2013
Managing breast cancers with low estrogen receptor and HER2 by drugging bothTodd W Miller
Breast Cancer Research : BCR|February 10, 2012
Initiating breast cancer by PIK3CA mutationTodd W Miller
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 21, 2005
Intrabody applications in neurological disorders: progress and future prospectsTodd W Miller, Anne Messer
The Oncologist|November 22, 2017
Trailblazing Precision Oncology for Rare Tumor SubtypesKevin Shee, Todd W Miller
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2023
Alpelisib Efficacy without Cherry-PI3King MutationsSteven Tau, Todd W Miller
Cancer Metastasis Reviews|January 25, 2023
The role of cancer cell bioenergetics in dormancy and drug resistanceSteven Tau, Todd W Miller
Plos One|November 26, 2019
Statistical determination of synergy based on Bliss definition of drugs independenceEugene Demidenko, Todd W Miller
Pharmacogenomics and Personalized Medicine|September 11, 2014
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathwaysSarah R Hosford, Todd W Miller
Pageof 9